Constantin Tamvakopoulos

List of Publications by Year
in descending order

57 papers	2,196 citations	304368 22 h-index	223531 46 g-index
57 all docs	57 docs citations	57 times ranked	3078 citing authors

#	Article	IF	Citations
1	A role for the melanocortin 4 receptor in sexual function. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11381-11386.	3.3	289
2	The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides. Journal of Biological Chemistry, 2003, 278, 22418-22423.	1.6	205
3	Design and Pharmacology ofN-[(3R)-1,2,3,4-Tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 662 Td (1-ylmet Agonist. Journal of Medicinal Chemistry, 2002, 45, 4589-4593.	2.9	187
4	Metabolism and Anticancer Activity of the Curcumin Analogue, Dimethoxycurcumin. Clinical Cancer Research, 2007, 13, 1269-1277.	3.2	173
5	Chemoembolization of Hepatocellular Carcinoma with Hepasphere 30â€“60ÂÎ¼m. Safety and Efficacy Study. CardioVascular and Interventional Radiology, 2014, 37, 165-175.	0.9	97
6	Search for Potential Markers for Prostate Cancer Diagnosis, Prognosis and Treatment in Clinical Tissue Specimens Using Amine-Specific Isobaric Tagging (iTRAQ) with Two-Dimensional Liquid Chromatography and Tandem Mass Spectrometry. Journal of Proteome Research, 2008, 7, 3146-3158.	1.8	92
7	Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Research and Therapy, 2010, 12, R147.	1.6	69
8	Therapeutic Effects of an Anti-Myc Drug on Mouse Pancreatic Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	66
9	Mass spectrometry for the quantification of bioactive peptides in biological fluids. Mass Spectrometry Reviews, 2007, 26, 389-402.	2.8	65
10	Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry. Mass Spectrometry Reviews, 2012, 31, 110-133.	2.8	62
11	Tollâ€like receptor 7 stimulates production of specialized proâ€resolving lipid mediators and promotes resolution of airway inflammation. EMBO Molecular Medicine, 2013, 5, 762-775.	3.3	62
12	Nurr1:RXRÎ± heterodimer activation as monotherapy for Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3999-4004.	3.3	61
13	Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-pip (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 171-175.	1.0	47
14	GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery. Bioconjugate Chemistry, 2014, 25, 813-823.	1.8	43
15	Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4564-4569.	1.0	42
16	Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methy (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3501-3505.	1.0	39
17	Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3701-3705.	1.0	35
18	In vivo evaluation and in vitro metabolism of leuprolide in miceâ€”mass spectrometryâ€based biomarker measurement for efficacy and toxicity. Journal of Mass Spectrometry, 2008, 43, 1381-1392.	0.7	33

#	Article	IF	Citations
19	Dexamethasone induces Ï‰3-derived immunoresolvents driving resolution of allergic airway inflammation. Journal of Allergy and Clinical Immunology, 2018, 142, 691-695.e4.	1.5	30
20	Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2074-2077.	1.0	26
21	Peptideâ€“Drug Conjugate GnRHâ€“Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth. Cancer Research, 2016, 76, 1181-1192.	0.4	24
22	2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1993-1996.	1.0	22
23	Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1913-1917.	1.0	21
24	Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2912-2915.	1.0	21
25	Pathogenic mitochondrial dysfunction and metabolic abnormalities. Biochemical Pharmacology, 2021, 193, 114809.	2.0	21
26	A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotanâ€Ⅱ. Plasma and brain tissue concentrations following administration in mice. Rapid Communications in Mass Spectrometry, 2007, 21, 2431-2438.	0.7	20
27	Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2106-2110.	1.0	20
28	Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable â€œclickâ€•oxime bond tethers and preclinical evaluation against prostate cancer. European Journal of Medicinal Chemistry, 2021, 211, 113018.	2.6	20
29	Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6524-6532.	1.0	19
30	Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy. Molecular Pharmaceutics, 2017, 14, 674-685.	2.3	19
31	Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3242-3247.	1.0	17
32	Oral Administration of Chios Mastic Gum or Extracts in Mice: Quantification of Triterpenic Acids by Liquid Chromatography-Tandem Mass Spectrometry. Planta Medica, 2011, 77, 1916-1923.	0.7	17
33	Evaluation of a Stable Gonadotropin-Releasing Hormone Analog in Mice for the Treatment of Endocrine Disorders and Prostate Cancer. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 613-623.	1.3	17
34	1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a Tic mimetic: Application in the synthesis of potent human melanocortin-4 receptor selective agonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3430-3433.	1.0	16
35	Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2330-2334.	1.0	16
36	Simultaneous Absolute Quantification of the Glucose-Dependent Insulinotropic Polypeptides GIP_{1â^'42} and GIP_{3â^'42} in Mouse Plasma by LC/ESI-MS/MS: Preclinical Evaluation of DP-IV Inhibitors. Journal of Proteome Research, 2009, 8, 3487-3496.	1.8	15

#	Article	IF	Citations
37	Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile. European Journal of Medicinal Chemistry, 2019, 166, 256-266.	2.6	15
38	Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4399-4405.	1.0	14
39	Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: Enhanced enzymatic stability and biological properties. European Journal of Medicinal Chemistry, 2012, 58, 237-247.	2.6	14
40	Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and inÂvivo efficacy. European Journal of Medicinal Chemistry, 2019, 176, 393-409.	2.6	13
41	Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC. Cancers, 2021, 13, 1901.	1.7	13
42	Analysis of thein vitro metabolites of diferuloylmethane (curcumin) by liquid chromatography â€" tandem mass spectrometry on a hybrid quadrupole linear ion trap system: newly identified metabolites. European Journal of Drug Metabolism and Pharmacokinetics, 2007, 32, 51-57.	0.6	12
43	Transarterial Embolization with Sorafenib in Animal Livers: A Pharmacokinetics Study. Journal of Vascular and Interventional Radiology, 2013, 24, 1657-1663.e1.	0.2	12
44	Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer. Frontiers in Oncology, 2021, 11, 608201.	1.3	12
45	Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4â€²-piperidine] based melanocortin subtype-4 receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4895-4900.	1.0	11
46	Versatile quarto stimuli nanostructure based on Trojan Horse approach for cancer therapy: Synthesis, characterization, in vitro and in vivo studies. Materials Science and Engineering C, 2017, 79, 605-612.	3.8	11
47	Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity. European Journal of Medicinal Chemistry, 2017, 126, 954-968.	2.6	10
48	Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury. Biochemical Pharmacology, 2022, 203, 115168.	2.0	10
49	Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4483-4486.	1.0	7
50	Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine. Journal of Medicinal Chemistry, 2022, 65, 271-284.	2.9	6
51	Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule. Oncotarget, 2017, 8, 37250-37262.	0.8	5
52	Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3KÎ± Enzyme. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 990-1002.	0.9	3
53	Abstract 2618: Gemcitabine based peptide conjugates: Overcoming the pitfalls of conventional therapies by targeted approaches. , 2015, , .		0
54	Abstract LB-260: A small molecule Myc inhibitor has therapeutic effects on mouse pancreatic and other cancers. , 2015, , .		0

#	Article	IF	Citations
55	Abstract B42: Therapeutic effects of an anti-myc drug on mouse pancreatic cancer. , 2015, , .		0
56	Abstract 230: Proteomic approaches in the discovery of novel drug targets or potential biomarkers in breast cancer. , 2017, , .		0
57	Abstract LB-262: Design, synthesis, and efficacy of MYC inhibitors in mouse pancreatic cancer. , 2018, , .		0